Categories

Above the Fold

TECH: The evolution of wireless in hospitals

Now that cell phones and Wi-fi have proven to be safe and essential for health care facilities, there’s a race on to get signals into those buildings. This is proving to have some interesting possibilities, but is also bringing some technical challenges to hospital technology managers. Frequently buildings are too dense to allow good cell phone signal, while increased demand for Wi-fi and VOIP is putting pressure on the ad-hoc Wi-fi networks being built up in many hospitals. One solution gaining traction is to locate PCS, cellular and paging, and Wi-fi services centrally and create a series of ceiling-based transmitters to amplify and distribute the various signals. One company in the forefront of this is InnerWireless, which has announced several installation wins in recent weeks. I recently spoke with Jim McCoy, chief technology officer of InnerWireless, and Tuomo Rutanen of Ekahau to find out a little more about what’s going on inside the wireless world for hospitals.

Wireless and Wi-fi are different. InnerWireless’ technology deploys Wi-fi, as well as PCS, cellular, 2 way radio, 2 way paging and other signals. Conventional practice for Wi-fi is to deploy those points throughout a floor or department. Innerwireless co locates those Wi-fi access points at one place per floor, combine their outputs and then injects them onto their distributed antenna, therefore giving every user the strength of multiple antenna to access. This enhances Wi-fi data and more importantly VOIP performance. There tend to be around 6 distributed antenna per typical 20,000 sq ft floor, each one up in a ceiling panel where it’s installed once and forgotten about. All other services (cellular, PCS, etc) are piped to the same access point from aggregated through a main console room. And of course once the central points are in for cellular, it’s probably more cost-effective to layer Wi-fi into that system than to do it with ad-hoc networks.

In addition InnerWireless, Ekahau, and others are developing the ability to track patients, products and equipment in a cost-effective real time manner using the Wi-fi network–an always-on alternative to RFID which works sort of like an “indoors GPS”. They are both deploying tracking tags on people and equipment, and the size and price of those tags is falling rapidly. Ekahau’s approach takes advantage of the existing Wi-fi network, whereas InnerWireless uses its installed antennas and adds several more battery-operated sensors (probably 20 more per floor) to extend the accuracy of its trackers. Innerwireless is running their tracking over a different system within their infrastructure and are using the 802.15.4 standard for the tags.

These are two innovative companies attacking a key problem for health care facilities. Given the problems hospitals have locating their staff, patients and other movable parts, expect this technology to spread rapidly.

 

FDA examining Oseltamivir risks by John Pluenneke

If you read FierceHealthcare, you had advance warning of this one on  Monday. The Wall Street Journal reported yesterday afternoon that the  Food and Drug Administration is probing as many as 12 deaths it  believes may be linked to oseltamivir (i.e. Tamiflu) in Japan.  According to the paper, all of the victims were children.

Quoting from the source:

The FDA said there were 32 reports of "neuropsychiatric" adverse events, 31 of which happened in Japan, and included abnormal behavior, hallucinations, convulsions and encephalitis. The agency said it received a report of two patients, ages 12 and 13, jumping out of their windows after receiving two doses of Tamiflu.

The antiviral, which is jointly distributed by Roche and Gilead Life Sciences, is considered the best available treatment for the H5N1 virus, although not everybody agrees it will work. Given the recent hype about the drug, this is a development worth watching closely. Apparently the FDA has known about these allegations for some time – as in for many months. Expect a lot of talk in the media about this story and its implications once it sinks in.

Also expect the story to take center stage in the fight in Washington over the liability protections vaccine makers and drug companies say they want …Update: On Friday, an FDA advisory panel said it could find no evidence linking Tamiflu with the deaths in Japan.  Meanwhile, in response to public pressure, Japan’s independent Pharmaceuticals and Medical Devices agency  said it will begin publishing detailed data on all reports of adverse events it recieves related to prescription drugs and medical devices starting in January 2006.

PHARMA/POLICY/INTERNATIONAL: Not all the wingnuts are in the US

Australia had some great news yesterday as the national team qualified for the soccer world cup, even though it’s only the 4th most popular team sport with the word "football" in the title in the country. But there was also some more bad news. The way that the national broadcaster ABC presented it as Australia’s rural doctors disappointed by Abbott’s abortion pill decision.

Abbott is not the drug company, it’s Tony Abbott the health minister. Because I randomly know his sister and parents, I can tell you that what’s not in the article is that Abbott is a devout Catholic who nearly became a priest. Meanwhile he’s been kicked around in the Australian press for kow-towing to the pharmacist lobby on pricing, and also for not forcing promised cuts in generic prices. He was also at the center of some more complex wrangling over drugs in the free trade pact that many on the left in Australia are very suspicious about, but where I felt they walked a tight-rope fairly well in getting the free-trade deal done.

But the reason given for the ban on RU-486 is that rural doctors wouldn’t be able to treat women using it. Well as evidenced from the statements by rural doctors managed just fine to treat women who spontaneously abort, that’s pure bunk.  Which leads us to the conclusion that yet again religion and ideology have trumped science at the highest levels of national decisions about drugs.

POLICY: Yet more Dartmouth proof about doing too much

We’re almost at the point that you know exactly what any study from the Dartmouth group is going to find before it’s published. Following the assessment last year that showed that the nations “Top 100” hospitals show a wide variety of difference in procedures in their ICUs, for no apparent difference in outcomes, the same result comes up again.  This time (with Stanford’s Lauren Baker playing a starring cameo) Wennberg, Fisher et al looked at Medicare spending on patients in the last two years of life in hospitals in California and once again geography is destiny. (Health Affairs article here)

The study found that reimbursements ranged from $19,745 per Medicare patient at Redwood Memorial Hospital in Humboldt County’s Fortuna to $88,661 at Garfield Medical Center in Monterey Park in the San Gabriel Valley

Sacramento was cheaper than the Bay Area which was in turn cheaper than Los Angeles.  And of course the outcomes were similar in all places and had little relation to the costs. Interestingly, hospital chain is also a predictor. Sutter, which isn’t exactly known by California’s health plans as being a low cost operator, did way less than Tenet. (although I don’t know if Redding Medical Center skewed the data by itself!)

Medicare spending was also higher in some large hospital systems. Sutter Health, which operates 27 hospitals in Northern California, spent $30,814 on average per Medicare patient in the last two years of life, compared with $46,323 at Tenet Healthcare Corp.

Given that these are the most expensive patients (the 10% that cost 50% of all dollars), and moreover “it’s my money dammit”, you’d think that our so-called conservative leaders would be seizing on this to try to do something about the practice variation problem. But it just seems to be accepted as some type of unintelligent design.

 

BLOGS: FierceHealthcare, free and daily

Just in case you’re here from the WSJ for the first time, I also write a newsletter digest called FierceHealthcare which goes out daily and summarizes all you need to know about health care news.  It’s news (albeit with context) rather than opinion and perspective, so it serves a different purpose to THCB.

The WSJ was slightly wrong as it’s published (i.e. owned) not by me but by a company called FierceMarkets who also put out several other excellent newsletters. 

And it’s free. Sign up here

PHYSICIANS: One doc’s look at his own care patterns

File this in the cleaning up my queue category, but there’s a pretty good article in last weeks NEJM about how a doctor judges himself.  I’d submit that apart from baseball players, and call center customer service rep, most of us don’t get the regular metricized feedback that would help us improve.

This doc, Richard Baron, surveyed a small sample of his practice and discovered (and I’m sure that he’s not alone) that although he and his staff were doing OK in servicing patients, and keeping them clinically in good shape, he was not doing so well communicating to them about how to manage their disease. So he needs to import a good dose of information therapy.

But this is a start. The only company I’ve ever worked where there was serious consultation via survey with staff and customers was a survey firm.  And to be fair, whatever the results of the survey, they didn’t seem to really change the organization’s behavior too much. Perhaps I should be surveying my clients and my readers….but I think many more doctors should be surveying their patients.

 

BLOGS/POLICY: Health Reform competition still on

Just another reminder….

Please don’t forget to enter your solutions for the health reform compeition that Eric Novack and I are running, into this post. Only 250 words to save the American health care system? You can do that, go on!

BLOGS: Ego surfing..

So the WSJ picks today, when I’m unable to get to post much, to send gads of people to THCB. Welcome, welcome, and please feel free to dig around in the categories to zero in on what you’re interested in. I’ve written a lot here in the last couple of years and at some point soon will try to put some of it together in a book-type format (if anyone’s interested).

Meanwhile, the WSJ article was about industry specific blogs. Two quick thoughts. One is that although it’s an industry within an industry, but HISTalk blog should be on the list. Second, Laura Landro who interviewed me for the story and did the write-up on me and THCB, has a very, very interesting story of her own about her intimate acquaintance with the health care system.

TECH: Cerner stock keeps going up

Cerner’s stock price is up another 5% today. It’s P/E is nearing 45.  And this is for a company that basically sells more services (i.e. consulting) than software. No doubt that the re-architecting of their technology back in the last Millenium paid off big time, but this recent spurt really is on no new news, other than GE overpaid for IDX.

But does this mean that one of the oft-mentioned candidates for takeover (Oracle is a frequent mention, but any big tech firm might do) is having another look?  Or would the really ballsy play to be shorting Cerner here? Here’s the chart, and yes we should all have bought in May.

Cern

Technorati: , , , , , ,

POLICY: Jamie Robinson on Managed Consumerism–innovative but missing the bigger picture.

Jamie Robinson is one of the best and brightest of the “younger” crop of health economists in America, and certainly has his ear to the ground of what’s going on in American health care in a way that few others (aside from Uwe Reinhardt who anyway I’d classify as being in the “elder” generation of health economists) seem to understand. He was one of the first in academia to see the potential of the capitated physician groups, and was also one of the first to understand the end of managed care. Most academics spend forever mining the archaeology of the longly dead. Jamie sticks closely to the recent past and hints at the future.

His latest, one of numerous articles in a bursting at the seams Health Affairs, is on Managed Consumerism. It’s an attempt, and not a bad one, to put a unified framework around both the CDHP movement and managed competition:

“consumerism and managed competition often are proposing different solutions to different problems, not different and incompatible solutions to the same problems.”

Robinson spends a little time explaining that the two come from different philosophies. Consumerism from individual consumers making choices at time of care mostly from solo docs paid fee for service and therefore, (not that he says it) politically promoted by those doctors. Managed competition relies on consumers making choices among different integrated HMOs/health plans which use multi-specialty groups that are incented to keep costs down (or at least neutral) by use of capitation and pre-payment. He goes onto note not why managed competition failed, but instead that health plans stopped using the techniques of managed care (such as small networks and utilization management). What he doesn’t say but what is true is that the regulation (the management part of “managed competition”) was never in place to force plans to do so, despite the fact that Alain Enthoven had worked out the mechanism a decade earlier. (BTW for those of you who care, the mechanism involves pooling large numbers of people, forcing health plans to offer them the same set of benefits, and making the people choose between health plans with actual post-tax dollars, thereby giving the health plans the incentive to reduce overall costs per population). That never happened in any population, because it requires substantial reform of the insurance market (We’ll get to that later, even if Robinson doesn’t). Because that never happened, managed care never put the mechanisms in place that consistently would reduce costs, and instead when push came to shove (and the system pushed back) managed care meekly gave up.  And then the managed care plans noticed that they could make more money just being old fashioned insurance companies.

Five years into that inflation spiral, employers and consumers are moaning again, and so now we get the plan that looks like a 1970s major medical with a high deductible, but we can dress it up and call it a consumer-directed plan…and it’s much better. Of course it remains a high deductible plan that is basically unmanaged beyond the deductible, and it by definition doesn’t do much to control the costs of the expensive people on whom (as all you THCB readers should know by now) 80% of the money is spent on.

So what is going to happen. I’m skipping his optimistic bit but here’s the pessimism

“Ever-higher consumer cost sharing and ever-tighter provider networks would threaten the efficiency and equity of the health care delivery system. Excessive consumer cost sharing reduces the social pooling of risk, transferring financial responsibility from the healthy to the sick, and potentially reduces efficiency by reimbursing episodic and acute care services more generously than preventive and chronic care services. Excessively narrow provider networks frustrate patients’ ability to match their preferences with provider characteristics and limit providers’ ability to compete broadly on the basis of price and quality at the time of care”

What Jamie thinks is coming next is of course the managed high deductible plan

“It is not hard to envisage high-deductible, narrow-network, tightly managed product designs where choice of providers and procedures is limited by consumers themselves in favor of affordability.

What comes next in his analysis is at once very useful and interesting, and also misses the point. He provides a schematic about how insurance companies should buy medical care from providers. He argues that they should change their benefits based on whether or not the service being received is either demand or supply inelastic….i.e. whether changing the way its paid for can influence the patient the provider or both.

Rob

 

As witnessed in this chart (Exhibit 2–click on it to see it more clearly), this is pretty innovative stuff, and I’m sure that lots of big consulting shops are even now stealing it to take to their insurance clients.

Robinson does something similar for the clinical care market by dividing it up into acute and chronic care episodes and whether or not there are efficiencies of scale in delivery systems or not. And there are some good additions that his confluting together the consumer world (the 80% of the people) with the managed care world (the 80% of the dollars) provides. Rightfully, he accuses the proponents of managed competition and CDHC of extrapolating essentially from the institutions they know, and his framework at least covers the real world.

But he starts to lose me when he concludes that the market has spoken and rejected the managed competition approach.

This is the moment for a second generation of consumer-driven health policies and products. The shortcomings of HMOs, capitation, IDSs, and the other components of managed competition have opened the way for alternative approaches to using market mechanisms for improving the health care system

Writing in the same issue of Health Affairs in an excellent piece that points out many of the foibles of consumer directed health care Bob Berneson of the Urban Institute points out what was right about Enthoven’s original vision

In the right hands, market competition ideas can be made consistent with this ethos. Alain Enthoven’s managed competition approach, for example, in the words of Uwe Reinhardt, was an attempt to “fuse a price-competitive framework for health care with production processes designed to produce medical treatments efficiently and with income transfers designed to achieve a desired level of social equity.” This sounds fine to me, because it might have been done in ways that did not threaten the foundation of trust. It’s just that markets haven’t followed Enthoven’s vision—for lots of reasons.

So Enthoven’s vision required regulatory reform that was not allowed to happen, because in the end it would have been bad for the providers of health care’s fiscal interests. Robinson knows that the real world won’t let theories like his work.  He even notes (even before it’s fully happened, not that it’ll be a secret to THCB readers) what’s going to go wrong with consumer-directed care.

However, consumer-driven health care suffers from its own shortcomings. Blunt cost-sharing provisions, unadjusted for the patient’s income or health status, will penalize the poor and the sick while allowing their wealthier and healthier compatriots to retain higher balances in their HSAs. Nonselective network designs, the dismantling of utilization management, and a reversion to fee-for-service payment will encourage spending for high-cost services that fall above the insurance deductible.

But while he believes that there is a chance for managed consumerism, he’s ignoring two factors that will cause managed consumerism to be the failure that both managed care has been and consumer directed health care is about to be.

First, the market for clinical care is dominated by policies and regulations set in the 1930s and 1960s, and that’s why we have the institutions (solo practice docs, FFS medicine, and more latterly physician-owned surgicenters and now specialty hospitals) that fit neatly into Robinson’s new chart but don’t make any real sense for the way health care ought to be delivered in any rational market, or for that matter in a state-designed system. So in the absence of massive reform, there is still no real way that we are going to have a system that does any better than provide the players in the system with what they think will be best for them. Hence the strongest proponents of HSAs have forever been the solo practice docs who in their delusion believe that it will enable them to directly bill their patients and get the insurance companies out of the middle. The political power of the providers (sometimes aligning the docs with and sometimes opposing them to the hospitals) will continue to push against any rationalization of their organization or behavior. So the management part of managed consumerism is seeking a fix from the workings of an invisible hand that providers will just bite off.

Second, and this is the crucial bit, the market for insurance — irrespective of how insurers pay doctors and providers — is rigged so that insurers are better off insuring healthy people. Robinson calls his section on how insurers pay providers The Market For Insurance Coverage. But he’s wrong, the market for insurance coverage is about how people buy health insurance, not how health insurers buy or contracts for care. In the US most people are going to continue to have insurance covered by their employer or the taxpayer irrespective of how much it costs. This drives to the heart of the problem. Because we live in a rich country with a virtually inelastic demand for care, and because upper income employees receive health care for which they are not aware of the cost at the insurance level or the provider level, the system can always increase its prices — knowing that it will increase its revenue more from the price increase than it will lose it by the price effect.

Of course some people can’t afford it (or their employers can’t) and they get tossed into the uninsured numbers. But because no-one is responsible for them, and no-one (i.e. no central government) has to concern itself with the overall costs, no one cares. The provider keeps doing more, and the insurer has the choice of doing the hard things and beating them down (which is expensive and inefficient) or the easy thing which is selecting its risks better and jacking up its rates to its clients.  It’ll lose a few, but no matter as it’ll stay more profitable on the ones it keeps.  Robinson know this very well, as it’s a story he told about Aetna in Health Affairs last year.

And as Paul Krugman wrote yesterday in the NY Times in his “Healthcare Economics 101” column, the real issue is that the market for health insurance cannot be solved in an efficient or frankly humane way if we don’t have a universal pool. In other words it needs to be “rigged” so that insurers are no longer better off insuring healthy people. That at least was the concept behind managed competition, and it’s the same concept behind single payer, et al. It was not the concept behind market-driven managed care and is the complete anathema to consumer directed health care as exists now (and will in the future given that United has bought Golden Rule). And that is the elephant in the room that Robinson fails to note, for all the innovation in his schema.

Without real insurance reform, whatever we do we are never going to solve the core problems of cost (or even cost-effectiveness) and uninsurance. Anything else is lipstick on the pig.

Technorati: , , <a href="http://technorati.com/tag/insurance, , , ,